TG Therapeutics Inc Announces Positive Topline Results from the ULTIMATE I & II Phase 3 Studies Conference Call Transcript
Greetings, and welcome to the TG Therapeutics ULTIMATE I & II Top Line Data Release Call. (Operator Instructions) As a reminder, this conference is being recorded.
It is now my pleasure to introduce your host, Ms. Jenna Bosco. Thank you. Please go ahead.
Thank you. Good morning, everyone, and thank you for joining us today to discuss the positive top line results from the ULTIMATE I & II trials. I'm Jenna Bosco, TG's Senior Vice President of Corporate Communications, and I welcome you all to our conference call today.
Following our safe harbor statement, Michael Weiss, our Executive Chairman and Chief Executive Officer, will review the top line results announced this morning, and then turn the call over to Dr. Larry Steinman, our Phase III Study Chair; and Dr. Ed Fox, our Phase II Study Chair and a Principal Investigator on our Phase III program, who will reflect on today's outcome.
Before we begin, I'd like to remind everyone that
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |